Endometriosis Market Analysis, Size, Share & Growth Forecast 2026–2034

Relugolix Combination Myfembree SPIRIT 1 and 2 75 Percent Dysmenorrhoea and 66 Percent Non-Menstrual Pelvic Pain Responder Rate Has Established the Fixed-Dose GnRH Antagonist Plus Oestradiol Plus Norethindrone Combination as the Once-Daily Endometriosis Treatment With Built-In Bone-Protective Add-Back.Myovant Sciences and Pfizer's Myfembree demonstrated 74.8% response rate for dysmenorrhoea and 58.5% for non-menstrual pelvic pain in SPIRIT 1 and 2, and the estradiol-norethindrone add-back therapy prevents the bone mineral density loss that limits plain GnRH agonist leuprolide to 6-month treatment courses. The fixed single-pill combination eliminates the separate add-back prescription management that had made GnRH-based endometriosis therapy administratively complex, and the GnRH antagonist's immediate suppression onset within days versus the 4-6-week flare period with GnRH agonists provides a more acceptable initiation experience. Myovant Sciences's loss of exclusivity pipeline and AbbVie's linzagolix-based combination competitor filing represents the commercial maturation of the GnRH antagonist combination class, and the competitive landscape will ultimately be determined by payer formulary positioning and prescriber preference between Myfembree, Orilissa, and emerging linzagolix combinations.

Elagolix Orilissa Titratable Oestradiol Suppression at 150 mg Partial or 200 mg Full Suppression Has Provided the Dose-Dependent Endometriosis Pain Control Allowing the Patient and Clinician to Balance Pain Relief Against the Hypoestrogenic Side Effects at the Lowest Effective Dose.Bayer's dienogest Visanne achieved approximately 35 million annual prescriptions globally by 2024 as the progestogen-only approach preferred in European ESHRE and Japanese endometriosis guidelines that position oral progestogen therapy before GnRH analogue escalation in the treatment algorithm. The progesterone receptor agonism of dienogest suppresses endometrial gland and stroma proliferation at ectopic implantation sites through antiproliferative and anti-inflammatory mechanisms that reduce lesion size and dysmenorrhoea with a tolerability profile that includes irregular bleeding as the primary management challenge. The low systemic oestrogen suppression of dienogest versus GnRH analogues allows indefinite long-term therapy without bone mineral density loss monitoring requirements, enabling maintenance treatment through the reproductive years that addresses endometriosis's chronic recurrent nature.

Laparoscopic Endometriotic Lesion Excision Providing Pain Relief and Fertility Improvement That Hormonal Medical Management Cannot Achieve for the Structural Deep Infiltrating Endometrioma Has Established the Surgical Treatment Role for the Structural Disease That Suppression Alone Cannot Resolve.AbbVie's anti-IL-1 compound and Bayer's anti-WNT programme represent immunological approaches to endometriosis therapy that aim to reduce the inflammatory microenvironment that sustains ectopic endometrial tissue without the hormonal axis suppression that creates contraceptive and hypo-oestrogenic effects. The unmet need for endometriosis treatment in women attempting conception is the most significant gap in current medical management, where all approved hormonal therapies are contraceptive and incompatible with fertility treatment cycles, leaving surgery as the only option for endometriosis management in women seeking pregnancy. Non-hormonal mechanism validation in Phase 2 trials would establish the first specific endometriosis therapy compatible with concurrent fertility treatment, addressing the largest unmet need in women's reproductive health where endometriosis is implicated in approximately 30-50% of female infertility.

For related market intelligence, see the Uterine Fibroids Market.